| 摘要: |
| 目的:观察2型糖尿病患者外周血单核细胞CD36的表达及罗格列酮对其表达的影响,探讨其可能的作用机制。方法:采用流式细胞仪测定2型糖尿病患者外周血单核细胞CD36的表达,并观察罗格列酮治疗后的变化；分析CD36与2型糖尿病各临床指标间的关系。结果:2型糖尿病组患者单核细胞CD36表达明显高于正常对照组(745.9±281.3 vs 406.3±80.2,P<0.01)；动脉粥样硬化组CD36表达明显高于无动脉粥样硬化组(878.2±296.1 vs 584.2±148.3,P<0.01)。罗格列酮治疗后,患者单核细胞CD36表达、空腹血糖(FBG)、餐后血糖(PBG)、HbA1c、空腹胰岛素(FIN)、餐后胰岛素(PIN)、胰岛素抵抗程度(HOMA-IR)均降低,与治疗前、安慰剂组均有统计学差异(P<0.05或P<0.01)。糖尿病患者单核细胞CD36表达与FBG(r=0.55,P<0.05)、HbA1c(r=0.62,P<0.01)、HOMA-IR(r=0.64,P<0.01)正相关,与PBG、FIN、PIN无明显相关。结论:罗格列酮可能通过有效控制血糖、降低胰岛素抵抗等途径来降低2型糖尿病患者外周血单核细胞CD36的表达。 |
| 关键词: CD36 2型糖尿病 单核细胞 动脉粥样硬化 罗格列酮 |
| DOI：10.3724/SP.J.1008.2009.0409 |
| 投稿时间：2008-03-07修订日期：2009-03-10 |
| 基金项目: |
|
| Effect of rosiglitazone on expression of CD36 in peripheral monocytes in patients with Type 2 diabetes |
| XU Mao-jin1,ZHAO Lin1,HAN Qiao-jun1,ZHANG Jun2,ZOU Da-jin1* |
| (1. Department of Endocrinology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China;2. Department of Laboratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433) |
| Abstract: |
| Objective:To observe the expression of CD36 in peripheral monocytes in patients with Type 2 diabetes, and to study the influence of rosiglitazone on CD36 expression and the related the mechanism. Methods: The expression of CD36 in the peripheral monocytes of patients with Type 2 diabetes was measured by flow cytometry before and after rosiglitazone treatment; the correlation between monocytes CD36 expression and metabolic index was analyzed. Results: Flow cytometry showed that the mean fluorescence intensity (MFI ) of monocyte CD36 in Type 2 diabetes was significantly higher than that in the healthy controls(745.9±281.3 vs 406.3±80.2,P<0.01). CD36 MFI in patients with Type 2 diabetes atherosclerosis was significantly higher than that in patients with Type 2 diabetes non-atherosclerosis(878.2±296.1 vs 584.2±148.3,P<0.01). Besides, we also found that CD36 expression, fasting blood glucose(FBG), post-prandial blood glucose(PBG), hemoglobin A1c(HbA1c), FIN, PIN, and HOMA-IR were all significantly decreased after rosiglitazone intervention compared with those before rosiglitazone intervetion and placebo group(P<0.05 or P<0.01). There was a positive correlation between monocyte CD36 expression with FBG(r=0.55,P<0.05), HbA1c(r=0.62,P<0.01), and HOMA-IR(r=0.64,P<0.01); but the expression was not correlated with PBG, FIN, or PIN. Conclusion: The increased expression of CD36 in monocytes of patients with Type 2 diabetes may be one of the mechanisms for accelerated atherosclerosis in diabetic patients. Rosiglitazone can decrease CD36 expression in monocytes through effectively controlling the blood glucose and decreasing insulin resistance. |
| Key words: CD36 type 2 diabetes mellitus monocytes atherosclerosis rosiglitazone |
